Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Diabetes Therapy
Published in: Diabetes Therapy 3/2016

Open Access 01-09-2016 | Review

Clinical Effectiveness of Liraglutide in Type 2 Diabetes Treatment in the Real-World Setting: A Systematic Literature Review

Authors: Amrita Ostawal, Emina Mocevic, Nana Kragh, Weiwei Xu

Published in: Diabetes Therapy | Issue 3/2016

Login to get access

Abstract

Introduction

In clinical trials, liraglutide has proven to be an effective drug for the treatment of type 2 diabetes mellitus (T2DM). The real-world effectiveness of liraglutide has been investigated in numerous studies. The aim of this systematic literature review is to collate evidence on the real-world clinical effectiveness of liraglutide.

Methods

A review of publications from Medline, EMBASE, the Cochrane Library, and conference proceedings was conducted to identify observational studies that assessed the clinical effectiveness of liraglutide in real-world clinical practice. This review was conducted according to the National Institute of Health and Care Excellence (NICE) guidance. No language or time limits were applied, except to the conference proceedings (2013–2015). Endpoints for data extraction were decided a priori. Study quality appraisal was done for full-text journal articles.

Results

Of 124 publications included in the review, 43 were full-text articles. Liraglutide significantly reduces glycated hemoglobin (HbA1c) within 6 months of initiating treatment (mean change in HbA1c from baseline: −0.9% to −2.2%; HbA1c <7.0%: 29.5–65.0%). The NICE composite endpoint (HbA1c reduction ≥1% and weight reduction ≥3%) was met in 16.9–47.0% of patients with liraglutide treatment. Liraglutide therapy led to a mean change in absolute weight from baseline of −1.3 to −8.65 kg. Liraglutide treatment was well tolerated in patients with T2DM. The rate of occurrence of hypoglycemia with liraglutide monotherapy was ≤0.8%. Hypoglycemia was more common in patients taking antidiabetic medications (0.0–15.2%) together with liraglutide. The beneficial glycemic and weight effect of liraglutide therapy in patients with T2DM was maintained for at least 12 months.

Conclusion

Evidence from observational studies reflecting real-world clinical practice demonstrates that liraglutide therapy improves glycemic control with a low risk of hypoglycemia, and is associated with significant weight loss in patients with T2DM. These observations are consistent with clinical trial findings.

Funding

Novo Nordisk A/S, Søborg, Denmark.
Appendix
Available only for authorised users
Literature
1.
2.
American Diabetes Association. Standards of medical care in diabetes—2014. Diabetes Care. 2014;37(Suppl 1):S14–80.CrossRef
3.
4.
5.
6.
7.
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140–9.PubMedCrossRef
8.
Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993;36(8):741–4.PubMedCrossRef
9.
Doyle ME, Egan JM. Mechanisms of Action of GLP-1 in the Pancreas. Pharmacol Ther. 2007;113(3):546–93.PubMedCrossRef
10.
11.
Marre M, Shaw J, Brandle M, Bebakar WM, Kamaruddin NA, Strand J, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med. 2009;26(3):268–78.PubMedPubMedCentralCrossRef
12.
Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32(1):84–90.PubMedPubMedCentralCrossRef
13.
Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373(9662):473–81.PubMedCrossRef
14.
Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD). Diabetes Care. 2009;32(7):1224–30.PubMedPubMedCentralCrossRef
15.
Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met + SU): a randomised controlled trial. Diabetologia. 2009;52(10):2046–55.PubMedPubMedCentralCrossRef
16.
Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374(9683):39–47.PubMedCrossRef
17.
Nauck M, Rizzo M, Pirags V. Once-daily liraglutide vs. lixisenatide as add-on to metformin in type 2 diabetes: a 26-week randomised controlled clinical trial. Abstract number 75. In: Presented at The 51st Annual Meeting of the European Association of Diabetes (EASD). 2015.
18.
Pratley RE, Nauck MA, Barnett AH, Feinglos MN, Ovalle F, Harman-Boehm I, et al. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes Endocrinol. 2014;2(4):289–97.PubMedCrossRef
19.
Dungan KM, Povedano ST, Forst T, González JGG, Atisso C, Sealls W, et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet. 2014;384(9951):1349–57.PubMedCrossRef
20.
Buse JB, Nauck M, Forst T, Sheu WHH, Shenouda SK, Heilmann CR, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet. 2013;381(9861):117–24.PubMedCrossRef
21.
Pratley RE, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet. 2010;375(9724):1447–56.PubMedCrossRef
22.
Pratley R, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, et al. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J Clin Pract. 2011;65(4):397–407.PubMedPubMedCentralCrossRef
23.
Pratley RE, Nauck MA, Bailey T, Montanya E, Filetti S, Garber AJ, et al. Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial. Diabetes Care. 2012;35(10):1986–93.PubMedPubMedCentralCrossRef
24.
Kaku K, Kiyosue A, Ono Y, Shiraiwa T, Kaneko S, Nishijima K, et al. Liraglutide is effective and well tolerated in combination with an oral antidiabetic drug in Japanese patients with type 2 diabetes: a randomized, 52-week, open-label, parallel-group trial. J Diabetes Investig. 2016;7(1):76–84.PubMedCrossRef
25.
Seino Y, Kaneko S, Fukuda S, Osonoi T, Shiraiwa T, Nishijima K, et al. Combination therapy with liraglutide and insulin in Japanese subjects with type 2 diabetes: a 36-week, randomized, double-blind, parallel-group trial. J Diabetes Investig. 2016. (Epub ahead of print).
26.
27.
Centre for Reviews and Dissemination. Systematic reviews: CRD’s guidance for undertaking reviews in healthcare. Centre for Reviews and Dissemination: University of York; 2009.
28.
Buysman EK, Liu F, Hammer M, Langer J. Impact of medication adherence and persistence on clinical and economic outcomes in patients with type 2 diabetes treated with liraglutide: a retrospective cohort study. Adv Ther. 2015;32(4):341–55.PubMedPubMedCentralCrossRef
29.
Buysschaert M, D’Hooge D, Preumont V, Roots Study Group. ROOTS: a multicenter study in Belgium to evaluate the effectiveness and safety of liraglutide (Victoza) in type 2 diabetic patients. Diabetes Metab Syndr. 2015;9(3):139–42.PubMedCrossRef
30.
Chiefari E, Capula C, Vero A, Oliverio R, Puccio L, Liguori R, et al. Add-on treatment with liraglutide improves glycemic control in patients with type 2 diabetes on metformin therapy. Diabetes Technol Ther. 2015;17(7):468–74.PubMedCrossRef
31.
Cotugno M, Nosso G, Saldalamacchia G, Vitagliano G, Griffo E, Lupoli R, et al. Clinical efficacy of bariatric surgery versus liraglutide in patients with type 2 diabetes and severe obesity: a 12-month retrospective evaluation. Acta Diabetol. 2015;52(2):331–6.PubMedCrossRef
32.
Evans M, McEwan P, O’Shea R, George L. A retrospective, case-note survey of type 2 diabetes patients prescribed incretin-based therapies in clinical practice. Diabetes Ther. 2013;4(1):27–40.PubMedCrossRef
33.
Evans M, McEwan P, O’Shea R, George L. Efficacité en pratique clinique courante des incrétino-mimétiques dans le traitement du diabète de type 2: résultats d’une enquête nationale rétrospective au Royaume-Uni. Méd Mal Métab. 2014;8(2):177–83.
34.
Fadini GP, Simioni N, Frison V, Dal Pos M, Bettio M, Rocchini P, et al. Independent glucose and weight-reducing effects of Liraglutide in a real-world population of type 2 diabetic outpatients. Acta Diabetol. 2013;50(6):943–9.PubMedCrossRef
35.
Funch D, Gydesen H, Tornoe K, Major-Pedersen A, Chan KA. A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs. Diabetes Obes Metab. 2014;16(3):273–5.PubMedCrossRef
36.
Gautier JF, Martinez L, Penfornis A, Eschwege E, Charpentier G, Huret B, et al. Effectiveness and persistence with liraglutide among patients with type 2 diabetes in routine clinical practice–EVIDENCE: a prospective, 2-year follow-up, observational, post-marketing study. Adv Ther. 2015;32(9):838–53.PubMedPubMedCentralCrossRef
37.
Ghuman NK, Saadah LM, Al Najjar MS, Shaheen DY, Am SI, Al Ali MM. Effectiveness of liraglutide in type II diabetes mellitus management: experience in emirati patients. Clin Med Insights Endocrinol Diabetes. 2015;8:67–72.PubMedPubMedCentral
38.
Inoue K, Maeda N, Fujishima Y, Fukuda S, Nagao H, Yamaoka M, et al. Long-term impact of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight and glycemic control in Japanese type 2 diabetes: an observational study. Diabetol Metab Syndr. 2014;6(1):95.PubMedPubMedCentralCrossRef
39.
Lapolla A, Frison V, Bettio M, Dal Pos M, Rocchini P, Panebianco G, et al. Correlation between baseline characteristics and clinical outcomes in a large population of diabetes patients treated with liraglutide in a real-world setting in Italy. Clin Ther. 2015;37(3):574–84.PubMedCrossRef
40.
Ohki T, Isogawa A, Iwamoto M, Ohsugi M, Yoshida H, Toda N, et al. The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone. ScientificWorldJournal. 2012;2012:496453.PubMedPubMedCentralCrossRef
41.
Perušičová J, Skupina, Pithová a pracovní P. Vliv inkretinového mimetika liraglutidu (Victoza) na hmotnost a hladiny glykovaného hemoglobinu u nemocných s diabetes mellitus 2. typu v diabetologických ordinacích ČR–studie BIVI. Interní medicína pro praxi. 2013;15(5):170–5.
42.
Ponzani P. Long-term effectiveness and safety of liraglutide in clinical practice. Miner Endocrinol. 2013;38(1):103–12.
43.
Rigato M, Avogaro A, Fadini GP. Effects of dose escalating liraglutide from 1.2 to 1.8 mg in clinical practice: a case-control study. J Endocrinol Invest. 2015;38(12):1357–63.PubMedCrossRef
44.
Russo GT, Labate AM, Giandalia A, Romeo EL, Villari P, Alibrandi A, et al. Twelve-month treatment with Liraglutide ameliorates Visceral Adiposity Index and common cardiovascular risk factors in type 2 diabetes outpatients. J Endocrinol Invest. 2015;38(1):81–9.PubMedCrossRef
45.
Thomsen RW, Baggesen LM, Sogaard M, Pedersen L, Norrelund H, Buhl ES, et al. Early glycaemic control in metformin users receiving their first add-on therapy: a population-based study of 4,734 people with type 2 diabetes. Diabetologia. 2015;58(10):2247–53.PubMedCrossRef
46.
Vitagliano G, Nosso G, Cotugno M, Saldalamacchia G, Lupoli R, Griffo E, et al. One-year efficacy of liraglutide or bariatric surgery in obese type 2 diabetic patients: a retrospective study. G Ital Diabetol Metabol. 2014;34(2):58–63.
47.
Zavattaro M, Caputo M, Sama MT, Mele C, Chasseur L, Marzullo P, et al. One-year treatment with liraglutide improved renal function in patients with type 2 diabetes: a pilot prospective study. Endocrine. 2015;50(3):620–6.PubMedCrossRef
48.
Bashier AM, Hussain AA, Abdelgadir EI, Eltinay AT, Thadani P, Abdalla ME, et al. Liraglutide effect in reducing HbA1c and weight in Arab population with type2 diabetes, a prospective observational trial. J Diabetes Metab Disord. 2015;14:48.PubMedPubMedCentralCrossRef
49.
Chitnis AS, Ganz ML, Benjamin N, Langer J, Hammer M. Clinical effectiveness of liraglutide across body mass index in patients with type 2 diabetes in the United States: a retrospective cohort study. Adv Ther. 2014;31(9):986–99.PubMedPubMedCentralCrossRef
50.
DeKoven M, Lee WC, Bouchard J, Massoudi M, Langer J. Real-world cost-effectiveness: lower cost of treating patients to glycemic goal with liraglutide versus exenatide. Adv Ther. 2014;31(2):202–16.PubMedPubMedCentralCrossRef
51.
Heymann A, Maor Y, Goldstein I, Todorova L, Schertz-Sternberg P, Karasik A. Efficacy of liraglutide in a real-life cohort. Diabetes Ther. 2014;5(1):193–206.PubMedPubMedCentralCrossRef
52.
Kesavadev J, Shankar A, Gopalakrishnan G, Jothydev S. Efficacy and safety of liraglutide therapy in 195 Indian patients with type 2 diabetes in real world setting. Diabetes Metab Syndr. 2015;9(1):30–3.PubMedCrossRef
53.
Kesavadev J, Shankar A, Krishnan G, Jothydev S. Liraglutide therapy beyond glycemic control: an observational study in Indian patients with type 2 diabetes in real world setting. Int J Gen Med. 2012;5:317–22.PubMedPubMedCentralCrossRef
54.
Kondo Y, Satoh S, Nagakura J, Kimura M, Nezu U, Terauchi Y. Defining criteria for the introduction of liraglutide using the glucagon stimulation test in patients with type 2 diabetes. J Diabetes Investig. 2013;4(6):571–5.PubMedPubMedCentralCrossRef
55.
Kondo Y, Satoh S, Osada UN, Terauchi Y. Early liraglutide treatment improves beta-cell function in patients with type 2 diabetes: a retrospective cohort study. Endocr J. 2015;62(11):971–80.PubMedCrossRef
56.
Li Q, Chitnis A, Hammer M, Langer J. Real-world clinical and economic outcomes of liraglutide versus sitagliptin in patients with type 2 diabetes mellitus in the United States. Diabetes Ther. 2014;5(2):579–90.PubMedPubMedCentralCrossRef
57.
Mezquita-Raya P, Reyes-Garcia R, Moreno-Perez O, Escalada-San Martin J, Angel Rubio Herrera M, Lopez de la Torre Casares M. Clinical effects of liraglutide in a real-world setting in Spain: eDiabetes-Monitor SEEN Diabetes Mellitus Working Group Study. Diabetes Ther. 2015;6(2):173–85.PubMedPubMedCentralCrossRef
58.
Nyeland ME, Ploug UJ, Richards A, Garcia Alvarez L, Demuth D, Muthutantri A, et al. Evaluation of the effectiveness of liraglutide and sitagliptin in type 2 diabetes: a retrospective study in UK primary care. Int J Clin Pract. 2015;69(3):281–91.PubMedCrossRef
59.
Rizzo MCM, Patti AM, Di Bartolo V, Rizvi AA, Montalto G, Abate N. Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study. Cardiovasc Diabetol. 2014;13:49.PubMedPubMedCentralCrossRef
60.
Thong KY, McDonald TJ, Hattersley AT, Blann AD, Ramtoola S, Duncan C, et al. The association between postprandial urinary C-peptide creatinine ratio and the treatment response to liraglutide: a multi-centre observational study. Diabet Med. 2014;31(4):403–11.PubMedCrossRef
61.
Toyoda M, Yokoyama H, Abe K, Nakamura S, Suzuki D. Predictors of response to liraglutide in Japanese type 2 diabetes. Diabetes Res Clin Pract. 2014;106(3):451–7.PubMedCrossRef
62.
Varanasi A, Patel P, Makdissi A, Dhindsa S, Chaudhuri A, Dandona P. Clinical use of liraglutide in type 2 diabetes and its effects on cardiovascular risk factors. Endocr Pract. 2012;18(2):140–5.PubMedCrossRef
63.
Ahern T, Tobin AM, Corrigan M, Hogan A, Sweeney C, Kirby B, et al. Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study. J Eur Acad Dermatol Venereol. 2013;27(11):1440–3.PubMedCrossRef
64.
Diaz-Soto G, de Luis DA, Conde-Vicente R, Izaola-Jauregui O, Ramos C, Romero E. Beneficial effects of liraglutide on adipocytokines, insulin sensitivity parameters and cardiovascular risk biomarkers in patients with Type 2 diabetes: a prospective study. Diabetes Res Clin Pract. 2014;104(1):92–6.PubMedCrossRef
65.
Gomez-Peralta F, Abreu C, Castro JC, Alcarria E, Cruz-Bravo M, Garcia-Llorente MJ, et al. An association between liraglutide treatment and reduction in excessive daytime sleepiness in obese subjects with type 2 diabetes. BMC Endocr Disord. 2015;15(1):78.PubMedPubMedCentralCrossRef
66.
Jinnouchi H, Sugiyama S, Yoshida A, Hieshima K, Kurinami N, Suzuki T, et al. Liraglutide, a glucagon-like peptide-1 analog, increased insulin sensitivity assessed by hyperinsulinemic-euglycemic clamp examination in patients with uncontrolled type 2 diabetes mellitus. J Diabetes Res. 2015;2015:706416.PubMedPubMedCentralCrossRef
67.
Kaur P, Mishra SK, Mithal A, Saxena M, Makkar A, Sharma P. Clinical experience with Liraglutide in 196 patients with type 2 diabetes from a tertiary care center in India. Indian J Endocrinol Metab. 2014;18(1):77–82.PubMedPubMedCentralCrossRef
68.
Mori Y, Taniguchi Y, Sezaki K, Yokoyama J, Utsunomiya K. Liraglutide narrows the range of circadian glycemic variations in Japanese type 2 diabetes patients and nearly flattens these variations in drug-naive type 2 diabetes patients: a continuous glucose monitoring-based study. Diabetes Technol Ther. 2011;13(11):1139–44.PubMedCrossRef
69.
Mulligan CM, Harper R, Harding J, McIlwaine W, Petruckevitch A, McLaughlin DM. A retrospective audit of type 2 diabetes patients prescribed liraglutide in real-life clinical practice. Diabetes Ther. 2013;4(1):147–51.PubMedPubMedCentralCrossRef
70.
Usui R, Yabe D, Kuwata H, Fujiwara S, Watanabe K, Hyo T, et al. Retrospective analysis of safety and efficacy of insulin-to-liraglutide switch in Japanese type 2 diabetes: a caution against inappropriate use in patients with reduced beta-cell function. J Diabetes Investig. 2013;4(6):585–94.PubMedPubMedCentralCrossRef
71.
Gomez-Peralta F, Castro JC, Alcarria E, Cruz-Bravo M, Garcia-Llorente MJ, Albornos C, et al. Almodovar influence of liraglutide treatment in obstructive sleep apnea (OSA) in patients with obesity and diabetes mellitus type 2; 2013.
72.
73.
DeKoven M, Lee W, Bouchard J, Edwy M, Langer J. Improved real-world glycemic outcomes with liraglutide versus other incretin-based therapies in type 2 diabetes. In: Presented at The American Diabetes Association (ADA) 73rd scientific sessions, June 21–25, Chicago, Illinois 2013.
74.
75.
Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15(6):540–59.PubMedCrossRef
76.
American Diabetes Association. Standards of medical care in diabetes - 2013. Diabet Care. 2013;36(1):S11–66.CrossRef
77.
Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Arterioscler Thromb Vasc Biol. 2006;26(5):968–76.PubMedCrossRef
78.
Gautier JF, Penfornis A, Charpentier G, Bouzidi A, Madani S, Martinez L, et al. The proportion of patients successfully treated with liraglutide—results from a post-hoc analysis of the EVIDENCE study. In: Presented at the 75th scientific sessions American Diabetes Association (ADA) 2015, June 5–9, 2015, Boston, MA, USA; 2015.
79.
Matsson P, Lind M, Johansson G, Svenningsson I, Jörgensen L, Ploug U, et al. A retrospective assessment of clinical effectiveness in type 2 diabetes patients treated with liraglutide or sitagliptin from primary care centers in Sweden. In: Presented at The SFD 7–8 May 2015; 2015.
80.
Heymann A, Maor Y, Goldstein I, Todorava L, Schertz-Sternberg P, Karasik A. Real life evidence of liraglutide effects supports efficacy shown in RCTs. In: Presented at The World Diabetes Congress, Melbourne, 2–6 December 2013; 2013.
81.
Karasik A, Heymann A, Sternberg P, Leshno M, Todorova L, Goldshtein I, et al. Real life effects of liraglutide supports those shown in RCTs. In: Presented at The ISPOR 16th Annual European Congress, Dublin; 2–6th November 2013.
82.
Fatima J, Pearce S. The use of GLP-1 agonist liraglutide: adhereing to guidelines? Diabetic Medicine. 2014;31(Suppl 1):28–123. Abstract P154. Abstracts of the Diabetes UK Professional Conference, 5–7 March 2014.
83.
Degn KB, Juhl CB, Sturis J, Jakobsen G, Brock B, Chandramouli V, et al. One week’s treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes. 2004;53(5):1187–94.PubMedCrossRef
84.
Mari A, Sallas WM, He YL, Watson C, Ligueros-Saylan M, Dunning BE, et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab. 2005;90(8):4888–94.PubMedCrossRef
85.
Buse JB, Sesti G, Schmidt WE, Montanya E, Chang CT, Xu Y, et al. Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes Care. 2010;33(6):1300–3.PubMedPubMedCentralCrossRef
86.
Thong KY, Sen Gupta P, Ryder REJ, ABCD nationwide exenatide and liraglutide audit contributors. The efficacy of exenatide and liraglutide among South Asians in the Association of British Clinical Diabetologists nationwide audits. In: Abstract book, 22nd World Diabetes Congress, IDF, Melbourne, Australia; 2–6 December 2013.
87.
88.
Zinman B, Buse J, Falahati S, Moses A. Attaining a clinically relevant endpoint of HbA1c <7.0%, no weight gain and no hypoglycaemia with liraglutide as compared to other therapies in type 2 diabetes mellitus: a meta-analysis of the LEAD studies. Diabetologia. 2009;52(Suppl 1):S291.
89.
Davies MJ, Kela R, Khunti K. Liraglutide—overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes. Diabetes Obes Metab. 2011;13(3):207–20.PubMedCrossRef
Metadata
Title
Clinical Effectiveness of Liraglutide in Type 2 Diabetes Treatment in the Real-World Setting: A Systematic Literature Review
Authors
Amrita Ostawal
Emina Mocevic
Nana Kragh
Weiwei Xu
Publication date
01-09-2016
Publisher
Springer Healthcare
Published in
Diabetes Therapy / Issue 3/2016
Print ISSN: 1869-6953
Electronic ISSN: 1869-6961
DOI
https://doi.org/10.1007/s13300-016-0180-0

Other articles of this Issue 3/2016

Diabetes Therapy 3/2016 Go to the issue

PRACTICAL APPROACH

A Practical Approach to Gastrointestinal Complications of Diabetes

Original Research

Persistence with Insulin Therapy in Patients with Type 2 Diabetes in France: An Insurance Claims Study

PRACTICAL APPROACH

Practical Approaches to Diabetes Care: An Introduction

Case Report

ABCC8-Related Maturity-Onset Diabetes of the Young (MODY12): Clinical Features and Treatment Perspective

Original Research

Saxagliptin Efficacy and Safety in Patients With Type 2 Diabetes and Moderate Renal Impairment

Original Research

Effect of Vildagliptin Versus Sulfonylurea in Muslim Patients with Type 2 Diabetes Fasting During Ramadan in Egypt: Results from VIRTUE Study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits